1. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Issue 10249 (15th August 2020) Authors: Folegatti, Pedro M; Ewer, Katie J; Aley, Parvinder K; Angus, Brian; Becker, Stephan; Belij-Rammerstorfer, Sandra; Bellamy, Duncan; Bibi, Sagida; Bittaye, Mustapha; Clutterbuck, Elizabeth A; Dold, Christina; Faust, Saul N; Finn, Adam; Flaxman, Amy L; Hallis, Bassam; Heath, Paul; Jenkin, Daniel; La... Journal: Lancet Issue: Volume 396:Issue 10249(2020) Page Start: 467 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Issue 1 (19th June 2015) Authors: von Delft, Annette; Humphreys, Isla S; Brown, Anthony; Pfafferott, Katja; Lucas, Michaela; Klenerman, Paul; Lauer, Georg M; Cox, Andrea L; Gaudieri, Silvana; Barnes, Eleanor Journal: Gut Issue: Volume 65:Issue 1(2016) Page Start: 112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗